HB712 creates a new Hawaii law to protect the federal 340B drug pricing program from manufacturer restrictions on contract pharmacies. The bill states that 340B covered entities, such as nonprofit hospitals, safety net providers, rural hospitals, community health centers, and Native Hawaiian health centers, rely on discounted drug purchases to serve low-income, uninsured, and geographically isolated patients. It finds that limiting contract pharmacy access can reduce medication access and weaken the financial support hospitals use for community benefits.
The bill prohibits drug manufacturers, and their agents or affiliates, from directly or indirectly denying, restricting, or prohibiting the acquisition, shipping, or delivery of 340B drugs to contract pharmacies authorized by a covered entity, unless federal law or HHS prohibits the transaction. It also allows manufacturers to request limited claims data for specified purposes such as investigating diversion, duplicate discounts, or rebate eligibility, subject to HIPAA and privacy-law compliance and a three-year lookback limit. The measure creates a four-year statute of limitations for enforcement actions and authorizes injunctive and equitable relief, attorney’s fees, and civil penalties enforced by the attorney general.
The bill also adds reporting requirements. Beginning July 1, 2026, each 340B covered entity must annually report to the state hospital trade association information about contract pharmacy use, including acquisition costs, insurer payments, prescription counts, and the number and location of contract pharmacies, including out-of-state sites. The hospital trade association must compile the submissions into an aggregate annual report and publicly post it starting October 1, 2027. In practical terms, the bill would expand state oversight of 340B contract pharmacy arrangements while preserving the federal program’s structure.
The general sentiment reflected in the bill text and voting history is strongly supportive. The findings emphasize access to care, rural health, and the importance of preserving savings that hospitals use for patient assistance and community services. The committee and conference votes listed were unanimous, indicating broad agreement across chambers and committees on the bill’s goals and approach.
The main point of contention addressed by the bill is the conflict between covered entities and drug manufacturers over contract pharmacy access and data requests. The bill sides with covered entities and the attorney general by banning manufacturer restrictions, but it preserves a limited right for manufacturers to seek claims data for anti-diversion and rebate-related purposes. The reporting provisions may also raise operational and privacy concerns for covered entities, but the bill attempts to address those issues by requiring HIPAA-compliant handling and limiting the scope of manufacturer data requests.
HB712 would add a new chapter to the Hawaii Revised Statutes governing the 340B drug discount program. It would create state-law prohibitions on manufacturer conduct affecting contract pharmacies, establish private and attorney general enforcement mechanisms, set civil penalties and remedies, impose a four-year limitations period, and require annual reporting by 340B covered entities and public aggregation by the state hospital trade association. The bill would primarily affect drug manufacturers, 340B covered entities, contract pharmacies, the attorney general, and the hospital trade association, while operating alongside federal 340B law.
The bill appears to have broad, bipartisan support and little visible opposition in the available record. It passed multiple Senate committees, Ways and Means, Judiciary, and conference committees unanimously or by unanimous votes, suggesting consensus around protecting access to discounted medications and supporting rural and underserved communities. The findings and report title frame the measure as an affordable health care and prescription drug access bill, reinforcing a generally favorable sentiment.
The central policy dispute is over manufacturer restrictions on 340B contract pharmacy arrangements. Supporters argue those restrictions undermine access to affordable medications, especially in rural Hawaii, and reduce hospital savings used for community benefits. Manufacturers’ concerns are partially acknowledged through a limited claims-data provision allowing requests tied to diversion, duplicate discounts, or rebate eligibility, but only within a three-year window and subject to privacy protections. The reporting requirements may also be a point of operational burden for covered entities, though the bill does not reflect significant recorded opposition in the voting history.